About ADDF

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder of the Estée Lauder cosmetics family, the Alzheimer’s Drug Discovery Foundation (ADDF) provides funding to leading scientists who are conducting the most promising, innovative Alzheimer’s drug research worldwide. Our goal is to provide seed funding for early-stage research that may otherwise go unfunded. By supporting cutting edge, diverse, novel research projects around the globe, we increase the chance of finding a cure.

Through the tremendous support of our donors, the ADDF has invested nearly $65 million to fund 450 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.

100% of your donation goes directly to Alzheimer’s drug research and related programs. All of the ADDF’s administrative and overhead costs are covered by a private foundation. 

In 2013, the ADDF launched its first international affiliate, ADDF-Canada. ADDF-Canada will provide funding to Canadian academic institutions and medical centers engaged in drug discovery and clinical trials to advance the development of novel therapeutics and diagnostic tools for Alzheimer’s disease, related dementias and cognitive aging. For more information on ADDF-Canada, please contact: Howard Fillit, MD, 212-901-800.